Fig. 4
From: Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
Differentially regulated genes in LRCCs with potential therapeutic value identified by a) Ingenuity Pathway Analysis (IPA). Only genes with a fold change > 2 and a FDR < 0.1 were considered, the highest scoring network is shown (genes selected for further analysis are highlighted). b) Validation of differential gene expression between LRCC and NLRCC cells identified on gene expression arrays by individual qRT-PCR